Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Total 13F shares
-
16,543,535
-
Share change
-
+1,096,665
-
Total reported value
-
$826,995,550
-
Put/Call ratio
-
119%
-
Price per share
-
$50.00
-
Number of holders
-
85
-
Value change
-
+$55,308,755
-
Number of buys
-
38
-
Number of sells
-
40
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q3 2020
As of 30 Sep 2020,
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,543,535 shares.
The largest 10 holders included
EPIQ Capital Group, LLC, Capital Research Global Investors, Capital World Investors, Capital International Investors, SC US (TTGP), LTD., BlackRock Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, STATE STREET CORP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.